---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-25-000023"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:14:35.267851+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027

## Summary
- Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).
- Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.
- New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.
- Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.
- Collateral remains substantially all assets; credit line with Pinnacle Bank.

## SEC filing metadata
- accession: 0001087294-25-000023
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/cpix-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-25-000023
- JSON: https://secwatch.observer/filing/0001087294-25-000023.json
- Plain text: https://secwatch.observer/filing/0001087294-25-000023.txt

## Key facts
- Debt Financings
  CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.
  - Instrument: revolving credit
  - Principal: up to $15 million
  - Counterparty: Pinnacle Bank
  - Rate: Benchmark Term SOFR plus 2.75%
  - Maturity: October 1, 2027
  - Event: incurrence
  source text: The Amendment provides for a principal available for borrowing of up to $15 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.